VX-765, an orally absorbed pro-drug of VRT-043198, is a potent and selective inhibitor of the ICE/caspase1 subfamily and is available for human use, making it an ideal candidate for human trials targeting EoE via NLRP3 downstream caspase1. This evidence concerns the gene NLRP3 and eosinophilic esophagitis.